Neurology

Biotechnology company bit.bio has launched a range of immune cells to provide researchers with a consistently functional and rapid human in vitro model for the study of neuroinflammation and neurodegenerative diseases.  The company’s ioMicroglia cell range is designed to recapitulate key human microglia functions and as such, can mediate inflammatory responses, dispose of unwanted materials, […]

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially effective treatment for concussion, which could change the […]

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. Register now to secure your place on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, […]

Register now to hear from neuroscience industry experts at ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. The online event will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, […]

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons. CRISPR-Ready ioGlutamatergic Neurons are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts and CRISPR screens. The potential applications include studies of […]

Register now to join this unique online event. Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny […]

Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Join this free webinar to learn about innovation taking place in the neuroscience field. You will hear from Fiona Elwood, VP, Disease […]

DDW has published the latest addition to its Guide Series, ‘Unlocking neuroscience drug discovery’. It covers the way the neuroscience sector is overcoming drug discovery challenges, advances in neuroscience and the era of precision neuroscience. Download to find out: Neuroscience drug discovery advances and challenges and how breakthroughs in this field are helping address areas […]

In this webinar, hosted by DDW and sponsored by ACROBiosystems, you will learn about the innovative advances in neuroscience. You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. Fiona Elwood will explore […]

A research team from VIB-KU Leuven and the UK Dementia Research Institute has discovered how neurons die in Alzheimer’s disease, opening new pathways for potential future treatments.  A new research paper published in Science illustrates how neurons initiate a programmed form of cell death, known as necroptosis, when they are exposed to amyloid plaques and […]

A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology company Faculty AI, has shown that computer models can […]

Researchers at University of Michigan (U-M) have developed a method to produce human brain organoids without animal cells that could improve the way neurodegenerative conditions are studied and treated. Human brain organoids are derived from embryonic or pluripotent stem cells and more closely model the complex brain structure compared to conventional two-dimensional cultures. Until now, […]

BioIVT has acquired PrecisionMed, a supplier of human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics. Based in Carlsbad, CA, US, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and reportedly has the largest private, global repository of longitudinally collected human CSF for […]

The independent Data Monitoring Committee (DMC) has recommended the continuation of Algiax Pharmaceuticals’ Phase IIa study with lead candidate AP-325 in chronic neuropathic pain. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France, and Italy. The study is continuing as planned with […]

PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group. There was also participation from existing investors including Cambridge […]

A new webinar is now available to watch anytime. CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the mouse model of CLN7 disease, and how the […]